Evogene Ltd. (EVGN) Stock Price & Analysis
Evogene Ltd. (EVGN) closed at USD 0.38 on Thursday, October 22, 2026, up 1.48% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 0.37; the Oct 22, 2026 session ranged USD 0.36–0.39 on volume of 10,104 shares. Market capitalization is $5.94M, with a 52-week range of USD 0.35–1.33 (NCM). Source: Nexqual, retrieved October 23, 2026 at 10:37 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EVGN.md
Key facts (EVGN)
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $693K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 2.15 (range 2.15–2.15).
- Total return with dividends: 1Y -69.3% vs S&P 500 +14.9%; 5Y -98.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-19, EPS estimate USD -0.19, revenue estimate $365K.
Insider purchases (SEC Form 4, open-market, last ~7 months) (EVGN)
3 purchases, $693K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-11 | Recanati Leon | Director | 460,000 | $292K | 0.64 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-04 | Recanati Leon | Director | 800,000 | $400K | 0.5 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04 | Tarcic Gabi | Chief Development Officer | 1,129 | $1K | 0.6 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (EVGN)
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 2.15 (low 2.15, high 2.15).
Total return (dividends reinvested) (EVGN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -69.3% | -98.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -69.5% | -57.4% |
| Volatility (annualized) | 79.1% | 70.4% |
| Max drawdown | -71.8% (Oct 2025→Oct 2026) | -98.6% (Nov 2021→Oct 2026) |
EVGN suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Corteva, Inc. (CTVA) | “Under the terms of the collaboration agreement, AgPlenus and Corteva” |
| Partner | Alphabet (Google) (GOOGL) | “We completed our first collaboration with Google Cloud in mid-2025” |
| Partner | AgPlenus | “advance through development in our partners' pipelines, and to the extent that they are commercialized by AgPlenus' collaboration” |
Quoted from the company's 20-F filed Mar 26, 2026.
Companies that name EVGN in their SEC reports
| Relationship to EVGN | Company | Filing | Sentence |
|---|---|---|---|
| supplier | Bioceres Crop Solutions Corp. (BIOX) | 20-F Nov 10, 2025 | “Other companies such as Evogene Ltd., INARI and DBNBC also engage in trait discovery and licensing technology to customers.” |
EVGN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.19 | $-0.27 | -29.6% | $365,000 | 1 |
| Next quarter (ends Dec 2026) | $-0.20 | $-0.27 | -25.9% | $390,000 | 1 |
| Current fiscal year (ends Dec 2026) | $-1.10 | $-1.70 | -35.3% | $1.4M | 1 |
| Next fiscal year (ends Dec 2027) | $-0.60 | $-0.80 | -25.0% | $2.6M | 1 |
Key Statistics (as of October 23, 2026 at 10:37 UTC)
| Price | USD 0.38 |
|---|---|
| Change | ▲ 1.48% (up) |
| Previous Close | USD 0.37 |
| Open | USD 0.36 |
| Day Range | USD 0.36 – 0.39 |
| 52-Week Range | USD 0.35 – 1.33 |
| Volume | 10,104 shares |
| Market Cap | $5.94M |
| Exchange | NCM |
Technical Analysis (EVGN)
Nexqual's technical model rates EVGN "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:37 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.32 (neutral) |
| vs SMA50 | Below (USD 0.48) |
| MACD | -0.03 (negative) |
Analyst Ratings (EVGN)
Wall Street analysts rate EVGN "Buy" based on 1 analysts, with a mean price target of USD 2.15 (range USD 2.15–2.15), per Nexqual as of October 23, 2026 at 10:37 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 2.15 |
| High Target | USD 2.15 |
| Low Target | USD 2.15 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (EVGN)
| Next Earnings Date | 2026-11-19 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $365,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.27 ▲ beat |
| 2026-03-31 | USD -0.61 vs est -0.27 ▼ miss |
| 2025-12-31 | USD -0.62 vs est -0.26 ▼ miss |
| 2025-09-30 | USD -0.46 vs est -0.41 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Financials & Fundamentals (EVGN)
| Total Revenue | $1.66M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -60.70% |
| Gross Margin | -67.59% |
| Operating Margin | -606.63% |
| Profit Margin | +0.00% |
| ROE | -182.75% |
| Debt / Equity | 0.36 |
| Current Ratio | 3.57 |
| Total Cash | $9.32M |
| Total Debt | $2.10M |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Financial Health Score (EVGN)
Nexqual rates Evogene Ltd.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:37 UTC.
| Growth | Critical — Revenue -55% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $9M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$11M (TTM) |
| Efficiency | Critical — ROE -183%, ROA -37.5% |
Ownership (EVGN)
| Insider Ownership | +32.40% |
|---|---|
| Institutional Ownership | +7.34% |
| Shares Outstanding | 15.80M |
| Float | 12.38M |
| Short % of Float | +5.94% |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Leadership (EVGN)
Evogene Ltd. is led by Ofer Haviv, CEO, President, CFO & Director, per Nexqual as of October 23, 2026 at 10:37 UTC.
| CEO, President, CFO & Director | Ofer Haviv |
|---|---|
| Chief Technology Officer | Ilia Zhidkov |
| Vice President of Human Resources | Liat Foigel Wejgman |
Major Backers & Investors (EVGN)
Notable institutional backers of Evogene Ltd. include SilverArc Capital Management, LLC, according to Nexqual as of October 23, 2026 at 10:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SilverArc Capital Management, LLC | 0.61% |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:37 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt